Metformin hydrochloride CAS 1115-70-4 is the hydrochloride salt of N,N-dimethylimidodicarbonimidic diamide, with an anhydrous molecular mass of 165.62 g/mol and the formula C₄H₁₁N₅·HCl. Pharma-grade API is manufactured and released against compendial monographs including USP-NF, Ph. Eur. 10.0, BP 2023, JP XVIII, IP 2022, and ChP 2020. The material is described as a white or almost white crystalline powder, freely soluble in water, slightly soluble in ethanol, and practically insoluble in acetone and methylene chloride. Release testing for oral solid-dose use normally includes an assay on the dried substance of 98.0 %–102.0 %, loss on drying not more than 0.5 %, residue on ignition not more than 0.1 %, and related substances by HPLC with total impurities not exceeding 1.0 %. The product is classified as a biguanide antihyperglycemic agent; its mechanism is not directly comparable to sulfonylureas, SGLT-2 inhibitors, or insulin secretagogues.

For tableting and encapsulation, Metformin HCl is distributed in several physical grades: standard crystalline, milled, direct-compression, and parenteral. Product model designations are not harmonized across compendia; commercial codes commonly distinguish direct-compression, wet-granulation, and parenteral grades by particle size and bioburden control, not by chemical identity. The main release-differentiating attribute between these grades is particle size distribution. Vendors commonly specify a D90 range of 150 µm–250 µm for wet-granulation feedstocks and 50 µm–150 µm for direct-compression grades; the finer direct-compression grade may have a D10 below 20 µm. Since metformin hydrochloride is a high-solubility molecule and is assigned to BCS Class III, dissolution from immediate-release tablets is frequently rapid in 0.1 N HCl medium under USP <711> Apparatus II at 50 rpm; the formulation problem is therefore not dissolution-mediated but arises from poor intrinsic compactibility, high elastic recovery, and moisture uptake. The common oral dose strengths of 500 mg, 850 mg, and 1000 mg create large die fill volumes that require high-speed rotary tablet presses with deep-fill cams and gravity or forced feeders designed for low-flow powders. Capsule filling of the same API requires granulated material with a controlled bulk density and flow function, typically after roller compaction or high-shear wet granulation.

Granulation-grade material is used in high-shear mixer granulations, fluid-bed granulations, and roller compaction. The aqueous solubility of metformin HCl means that water-based granulation can proceed without pH adjustment, but the same property creates a narrow liquid addition window: too little water yields weak granules, while too much water causes localized dissolution, re-crystallization, and densification. For this reason, a binder such as povidone K30 at 3 %–5 % of dry granule mass is often dissolved in the granulating fluid to maintain granule strength without excessive moisture. After drying, granule moisture is typically controlled at 1.0 %–2.5 % before compression; process controls for final blend uniformity should follow FDA 21 CFR 211.110 sampling requirements. The API also requires storage in tightly closed containers because moisture uptake above 60 % RH promotes powder consolidation and sticking on punch faces.

What Solid-Dose Process Conditions Are Specific to Metformin HCl Tableting?

In high-shear wet granulation, metformin HCl exhibits a short wet massing time tolerance. On a production-scale vertical granulator with an impeller speed of 100–200 rpm and a chopper speed of 1500–3000 rpm, granule growth advances rapidly once the liquid-to-solid ratio exceeds approximately 6 %–9 % w/w. The endpoint is therefore monitored by impeller torque or power consumption rather than by granulation time alone. Over-granulated batches are dense and poorly compressible; under-granulated batches generate high fines and segregate during transfer. The recommended order of addition is to pre-blend metformin HCl with the diluent for 2–5 min before adding the binder solution, because direct contact of the API with concentrated binder solutions can form hard, coarse agglomerates that survive drying and milling.

Roller compaction is an alternative for moisture-sensitive or heat-sensitive processes. In roller-compacted metformin HCl formulations, the granule is produced by dry granulation with a roll pressure commonly in the range of 40–120 kN, a roll gap of 1.5–2.5 mm, and an integral mill screen aperture of 0.8–1.25 mm. The compacted ribbons show a higher bulk density than wet-granulated material, which improves die fill at high tablet press speeds. However, dry granulation can reduce tablet tensile strength because metformin HCl particles undergo brittle fracture during milling; this necessitates a higher proportion of a plastically deformable binder, such as microcrystalline cellulose, and limits the use of brittle diluents like dibasic calcium phosphate anhydrous in high-load formulations. The loss on drying after roller compaction is not a useful endpoint because no solvent is added; instead, blend segregation is controlled by the fine fraction below 75 µm, which should not exceed 30 % if uniform weight is required.

Lubricant blending is a critical parameter for metformin HCl tablets. Magnesium stearate is usually added as a final blend at 0.5 %–1.0 % w/w. When total blending time after lubricant addition exceeds 15–20 min at 25 rpm in a bin blender, tablet hardness can fall by more than 10 % and disintegration time can increase because the hydrophobic lubricant is delaminated over granule surfaces. The effect is more pronounced in direct-compression formulations than in wet-granulated ones. This process conflict requires the use of a lubricant with a small particle size and a predetermined optimal blend time established by tablet hardness, ejection force, and dissolution release data under USP <701> disintegration and USP <711> dissolution.

Injectable-Grade Metformin Hydrochloride: Endotoxin, Particulate, and Solvent Boundaries

Parenteral and ophthalmic use of metformin HCl is not represented by the same release specification as oral-grade material. Injectable-grade API must be controlled for bacterial endotoxins, bioburden, particulate matter, and residual solvents at the point of manufacture. The bacterial endotoxin limit is not a fixed monograph value but is derived from the maximum intended bolus dose and the threshold pyrogenic dose of 5 EU/kg body mass according to USP <85> and Ph. Eur. 2.6.14. For a product intended for intravenous administration, the finished product must also meet USP <788> particulate matter limits appropriate for the container volume; for large-volume parenterals this is not more than 25 particles/mL ≥ 10 µm and not more than 3 particles/mL ≥ 25 µm. Sterile bulk metformin HCl is typically double-bagged and supplied in containers appropriate for aseptic processing under ISO 14644-1 class 5 or equivalent EU GMP Annex 1 grade A conditions.

Residual solvent control for injectable grade follows ICH Q3C with Class 1 solvents such as benzene not used, Class 2 solvents limited to their permitted daily exposure, and Class 3 solvents limited to 5000 ppm or justified by the intended maximum daily dose. The injectable grade should also be tested for elemental impurities according to ICH Q3D and USP <232>/<233>; parenteral risk assessment may impose lower permitted daily exposure limits than oral products for elements such as arsenic, cadmium, lead, and mercury. Because metformin HCl is freely soluble in water, aseptic filtration of the finished drug product is feasible, but the API itself is not a sterile filtered solution; terminal sterilization of the filled product may expose metformin HCl to hydrolytic degradation if not controlled. Published data for high-concentration injectable metformin HCl formulations are limited; stability indicating methods for assay and related substances should be validated under ICH Q1A(R2) and ICH Q2(R1) before release.

Metformin hydrochloride is not directly interchangeable with the free base or with other biguanide salts in an existing immediate-release or extended-release formula. The free base is a stronger base and exhibits different dissolution behavior; other salt forms such as metformin embonate have lower aqueous solubility and altered compaction behavior, requiring redevelopment of the dissolution method and stability-indicating assay. Compared with metformin hydrochloride, phenformin and buformin are older biguanide drugs that were withdrawn or restricted in many markets because of a higher incidence of lactic acidosis; their use in a formulated product would not be justified by the same safety data package. Metformin HCl is therefore the only usual biguanide salt for pharmaceutical tablet, capsule, granule, and injectable development. In extended-release products, the high aqueous solubility of metformin HCl means that matrix swelling and diffusion control are more relevant than dissolution-rate modification of the API particle surface. Typical extended-release matrices use hypromellose or polyethylene oxide at levels of 20 %–40 % of tablet mass; the active substance dissolves rapidly once the matrix erodes, so tablet robustness depends on matrix integrity rather than particle-size control alone.

Substitution of one physical grade for another within the same route may be considered a change in formulation under FDA SUPAC-IR/MR guidance; a change in particle size distribution from D90 250 µm to D90 80 µm may alter blend uniformity and dissolution. If the change is outside the approved design space, a post-approval supplement and stability study are required. The same principle applies to a change from USP metformin HCl to Ph. Eur. material when the supplier uses a different salt formation process or different residual solvent profile.

If Direct Compression Is Selected Instead of Roller Compaction or Wet Granulation

Direct compression of metformin HCl is technically possible but the processing window is narrow. The API has high elastic recovery and a low tensile strength at low compression force; tablets may cap or laminate when the press speed exceeds 30–50 rpm on a 45-station rotary press, particularly if the punch penetration depth is too shallow. The formulation must contain a plastically deformable filler such as microcrystalline cellulose and a disintegrant such as crospovidone at 2 %–5 % w/w. Direct-compression grade metformin HCl also requires a flow aid, typically colloidal silicon dioxide at 0.25 %–0.5 %, because the milled powder is cohesive and prone to ratholing in hoppers. Magnesium stearate lubrication above 1.0 % or blending longer than 15 min can reduce tablet hardness and delay dissolution of the low-porosity tablets. The tablet press compression force should be optimized with a force-displacement profile rather than fixed force alone; pre-compression force of 2–5 kN can reduce capping by allowing air to escape. Even with these controls, direct compression is generally limited to lower-dose combination products or specialized formulations; for 500 mg or 850 mg monotherapy tablets, wet granulation or roller compaction remains the more robust manufacturing route.

Moisture sensitivity during direct compression is a batch-to-batch variable. When the ambient humidity exceeds 60 % RH, the fine direct-compression metformin HCl takes up surface moisture and compacts become softer; sticking to punch faces is observed more frequently in high-speed compression. In such cases, the powder bed should be conditioned in a humidity-controlled booth at 35 %–45 % RH before feeding. The correlation between moisture content and tablet hardness is not linear; above 1.0 % moisture, tensile strength falls faster than predicted by the Heckel model. For this reason, direct-compression development should include a design of experiments that varies moisture content, lubricant level, and press speed, with responses of tablet hardness, friability, ejection force, and dissolution according to USP <711>.